CCR5 and atherosclerosis: These data for the first time confirm in the clinical setting the results obtained in vitro and in animal models5 according to which MVC is able to limit PI treatment induced atherosclerosis progression, and support cohort study data reporting a lower incidence of cardiovascular events in CCR5-Δ32-carrying patients4.